NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas

Holger Borchers, Frederick J. Meyers, Paul H. Gumerlock, Susan L. Stewart, Ralph W. Devere White

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: To investigate whether NM23 (nm23-H1, nm23-H2), a metastasis suppressor gene family, is a molecular marker indicative of metastatic potential of localized carcinoma of the prostate (CaP). Previously, we found decreased nm23-H2 expression correlated with an increase in stage, and here we have expanded the cohort. Materials and Methods: Eighty prostate tissue samples from patients with CaP and benign prostatic hyperplasia (BPH) were examined by quantitative reverse transcriptase polymerase chain reaction (RT- PCR) for NM23 gene expression. Samples were grouped according to stage, grade and whether the patient received combined androgen blockade (CAB) prior to surgery. Results: We could not confirm our initial results of an inverse correlation of nm23-H2 expression levels with grade. However, two significant results were found after CAB: 1) nm23-H1 expression was reduced (p = 0.003), and 2) nm23-H2 expression across stage and grade was uniformly higher (p = 0.003) than in untreated samples. Conclusion: NM23 appears not to be a useful molecular marker of metastatic potential in CaP. The altered gene expression after CAB may relate to a cancer cell subpopulation insensitive to apoptosis induced by hormone withdrawal.

Original languageEnglish (US)
Pages (from-to)2080-2084
Number of pages5
JournalJournal of Urology
Volume155
Issue number6
DOIs
StatePublished - Jun 1996

Fingerprint

Prostatic Hyperplasia
Androgens
Prostate
Carcinoma
Gene Expression
Tumor Suppressor Genes
Reverse Transcriptase Polymerase Chain Reaction
Hormones
Apoptosis
Neoplasms

Keywords

  • biological
  • polymerase chain reaction
  • prostatic neoplasms
  • tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

@article{da8bf3126a7f4b4c8c0a111fe9db2415,
title = "NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas",
abstract = "Purpose: To investigate whether NM23 (nm23-H1, nm23-H2), a metastasis suppressor gene family, is a molecular marker indicative of metastatic potential of localized carcinoma of the prostate (CaP). Previously, we found decreased nm23-H2 expression correlated with an increase in stage, and here we have expanded the cohort. Materials and Methods: Eighty prostate tissue samples from patients with CaP and benign prostatic hyperplasia (BPH) were examined by quantitative reverse transcriptase polymerase chain reaction (RT- PCR) for NM23 gene expression. Samples were grouped according to stage, grade and whether the patient received combined androgen blockade (CAB) prior to surgery. Results: We could not confirm our initial results of an inverse correlation of nm23-H2 expression levels with grade. However, two significant results were found after CAB: 1) nm23-H1 expression was reduced (p = 0.003), and 2) nm23-H2 expression across stage and grade was uniformly higher (p = 0.003) than in untreated samples. Conclusion: NM23 appears not to be a useful molecular marker of metastatic potential in CaP. The altered gene expression after CAB may relate to a cancer cell subpopulation insensitive to apoptosis induced by hormone withdrawal.",
keywords = "biological, polymerase chain reaction, prostatic neoplasms, tumor markers",
author = "Holger Borchers and Meyers, {Frederick J.} and Gumerlock, {Paul H.} and Stewart, {Susan L.} and {Devere White}, {Ralph W.}",
year = "1996",
month = "6",
doi = "10.1016/S0022-5347(01)66113-5",
language = "English (US)",
volume = "155",
pages = "2080--2084",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias

T2 - Altered expression in combined androgen blockaded carcinomas

AU - Borchers, Holger

AU - Meyers, Frederick J.

AU - Gumerlock, Paul H.

AU - Stewart, Susan L.

AU - Devere White, Ralph W.

PY - 1996/6

Y1 - 1996/6

N2 - Purpose: To investigate whether NM23 (nm23-H1, nm23-H2), a metastasis suppressor gene family, is a molecular marker indicative of metastatic potential of localized carcinoma of the prostate (CaP). Previously, we found decreased nm23-H2 expression correlated with an increase in stage, and here we have expanded the cohort. Materials and Methods: Eighty prostate tissue samples from patients with CaP and benign prostatic hyperplasia (BPH) were examined by quantitative reverse transcriptase polymerase chain reaction (RT- PCR) for NM23 gene expression. Samples were grouped according to stage, grade and whether the patient received combined androgen blockade (CAB) prior to surgery. Results: We could not confirm our initial results of an inverse correlation of nm23-H2 expression levels with grade. However, two significant results were found after CAB: 1) nm23-H1 expression was reduced (p = 0.003), and 2) nm23-H2 expression across stage and grade was uniformly higher (p = 0.003) than in untreated samples. Conclusion: NM23 appears not to be a useful molecular marker of metastatic potential in CaP. The altered gene expression after CAB may relate to a cancer cell subpopulation insensitive to apoptosis induced by hormone withdrawal.

AB - Purpose: To investigate whether NM23 (nm23-H1, nm23-H2), a metastasis suppressor gene family, is a molecular marker indicative of metastatic potential of localized carcinoma of the prostate (CaP). Previously, we found decreased nm23-H2 expression correlated with an increase in stage, and here we have expanded the cohort. Materials and Methods: Eighty prostate tissue samples from patients with CaP and benign prostatic hyperplasia (BPH) were examined by quantitative reverse transcriptase polymerase chain reaction (RT- PCR) for NM23 gene expression. Samples were grouped according to stage, grade and whether the patient received combined androgen blockade (CAB) prior to surgery. Results: We could not confirm our initial results of an inverse correlation of nm23-H2 expression levels with grade. However, two significant results were found after CAB: 1) nm23-H1 expression was reduced (p = 0.003), and 2) nm23-H2 expression across stage and grade was uniformly higher (p = 0.003) than in untreated samples. Conclusion: NM23 appears not to be a useful molecular marker of metastatic potential in CaP. The altered gene expression after CAB may relate to a cancer cell subpopulation insensitive to apoptosis induced by hormone withdrawal.

KW - biological

KW - polymerase chain reaction

KW - prostatic neoplasms

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0029868797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029868797&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)66113-5

DO - 10.1016/S0022-5347(01)66113-5

M3 - Article

C2 - 8618340

AN - SCOPUS:0029868797

VL - 155

SP - 2080

EP - 2084

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -